PMID- 8180325
OWN - NLM
STAT- MEDLINE
DCOM- 19940615
LR  - 20171116
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 4 Suppl 1
DP  - 1993 Dec
TI  - An international multicentre study: Clivarin in the prevention of venous 
      thromboembolism in patients undergoing general surgery. Report of the 
      International Clivarin Assessment Group.
PG  - S21-2
AB  - A randomized multicentre double-blind study was organized to evaluate the 
      efficacy and the safety of Clivarin (reviparin-sodium) (anti-Xa/anti-IIa ratio: 
      3-5 International units) for the prevention of post-operative thromboembolism in 
      patients undergoing general surgery. 1,351 patients were randomly allocated to 
      receive subcutaneously either 5,000 U of unfractionated heparin (UFH) twice a day 
      or 1,750 anti-Xa IU of reviparin-sodium once a day (morning) followed by a 
      placebo injection (evening) for at least 6 days. Deep vein thrombosis (DVT) was 
      detected with the 125I-fibrinogen technique confirmed by phlebography if 
      necessary. After randomization thrombotic risk factors were equally distributed 
      in each group. More than 50% of the patients had a cancer. The incidence of DVT 
      and of pulmonary embolism was 4.8% (CI 95%: 3.3-6.7%) in the reviparin-sodium 
      group and 4.4% (CI 95%: 2.9-6.2%) in the UFH group, a non-significant difference. 
      The number of transfusions required was equivalent in the two groups. However, 
      post-operative bleeding complications, including wound haematomas and internal 
      bleeding, were less frequent in the reviparin-sodium group (P < 0.01). Therefore, 
      for the first time, this study demonstrates that an unusual low dose of a low 
      molecular weight heparin retains its antithrombotic efficacy by comparison with 
      UFH and that the tolerance of this low dose is better.
FAU - Boneu, B
AU  - Boneu B
AD  - Laboratoire d'Hemostase, C.H.R. Toulouse, Hopital Purpan, France.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5R0L1D739E (reviparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Double-Blind Method
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/adverse effects/therapeutic use
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - Pulmonary Embolism/epidemiology/*prevention & control
MH  - Risk Factors
MH  - Thrombophlebitis/epidemiology/*prevention & control
MH  - Treatment Outcome
EDAT- 1993/12/01 00:00
MHDA- 1993/12/01 00:01
CRDT- 1993/12/01 00:00
PHST- 1993/12/01 00:00 [pubmed]
PHST- 1993/12/01 00:01 [medline]
PHST- 1993/12/01 00:00 [entrez]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 1993 Dec;4 Suppl 1:S21-2.